Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Bausch + Lomb Corp (NYSE:BLCO) is reportedly considering a sale as it navigates separation issues from its parent company, ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation ...

Bausch+Lomb, valued at over $10 billion ... with nearly 60% coming from contact lenses and eye drugs. The potential sale is part of efforts to address concerns from creditors like Apollo Global ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Investors who lost patience in Bausch Health (BHC) at below $6.00 this past summer missed out. Last week, rumors circulated that Bausch & Lomb (BLCO) is considering a buyout. Lenders have concerns ...

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...